Lannett Co (NYSE: LCI) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Lannett Co and BioLife Solutions, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lannett Co 0 3 2 0 2.40
BioLife Solutions 0 0 2 0 3.00

Lannett Co presently has a consensus target price of $21.00, indicating a potential upside of 22.09%. BioLife Solutions has a consensus target price of $5.50, indicating a potential upside of 13.40%. Given Lannett Co’s higher probable upside, analysts plainly believe Lannett Co is more favorable than BioLife Solutions.

Profitability

This table compares Lannett Co and BioLife Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lannett Co -0.09% 19.80% 6.42%
BioLife Solutions -63.71% -64.98% -35.19%

Volatility and Risk

Lannett Co has a beta of 2.74, indicating that its share price is 174% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lannett Co and BioLife Solutions’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Lannett Co $637.34 million 1.01 $245.00 million ($0.03) -573.14
BioLife Solutions $9.31 million 6.89 -$2.21 million ($0.47) -10.32

Lannett Co has higher revenue and earnings than BioLife Solutions. Lannett Co is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

88.1% of Lannett Co shares are held by institutional investors. Comparatively, 2.6% of BioLife Solutions shares are held by institutional investors. 15.0% of Lannett Co shares are held by company insiders. Comparatively, 37.7% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lannett Co beats BioLife Solutions on 9 of the 12 factors compared between the two stocks.

About Lannett Co

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

About BioLife Solutions

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.